Trending

Sanofi

LEO eyeing 2021 US launch for eczema drug tralokinumab

LEO Pharma is gearing up to launch its eczema drug tralokinumab next year after submitting a filing to the

X

LEO eyeing 2021 US launch for eczema drug tralokinumab

https://pharmaphorum.com/news/leo-eyeing-2021-us-launch-for-eczema-drug-tralokinumab/

Kymera Therapeutics begins potential $2bn R&D deal with Sanofi

Kymera Therapeutics begins potential $2bn R&D deal with Sanofi

US biotech Kymera Therapeutics has begun a strategic collaboration with Sanofi to develop and market several drugs tackling immune-inflammatory disease, which

X

Kymera Therapeutics begins potential $2bn R&D deal with Sanofi

https://pharmaphorum.com/news/kymera-therapeutics-begins-potential-2bn-rd-deal-with-sanofi/

Kiadis Pharma and Sanofi to unlock power of natural killer cells in multiple myeloma

Kiadis Pharma and Sanofi to unlock power of natural killer cells in multiple myeloma

Sanofi has struck an exclusive rights deal with Dutch biotech Kiadis focused on combining modified natural killer cells

X

Kiadis Pharma and Sanofi to unlock power of natural killer cells in multiple myeloma

https://pharmaphorum.com/news/sanofi-to-develop/

GSK and Sanofi close in on £500m COVID-19 vaccine deal with UK – report

GSK and Sanofi close in on £500m COVID-19 vaccine deal with UK – report

GlaxoSmithKline and Sanofi are close to agreeing a £500m deal to supply the UK government with 60 million

X

GSK and Sanofi close in on £500m COVID-19 vaccine deal with UK – report

https://pharmaphorum.com/news/gsk-and-sanofi-close-in-on-500m-covid-19-vaccine-deal-with-uk-report/

IL-6 hypothesis looking shaky as Kevzara fails COVID-19 trial

IL-6 hypothesis looking shaky as Kevzara fails COVID-19 trial

Hopes that already-approved drugs targeting IL-6 could be repurposed to treat COVID-19 have been undermined by disappointing results

X

IL-6 hypothesis looking shaky as Kevzara fails COVID-19 trial

https://pharmaphorum.com/news/il-6-hypothesis-looking-shaky-as-kevzara-fails-covid-19-trial/

Hand Sanitizer Market will touch USD 3.6 billion by 2026

Hand Sanitizer Market will touch USD 3.6 billion by 2026

Global Hand Sanitizer Market size is projected to surpass USD 3.6 billion through 2026, growing at a CAGR of

X

Hand Sanitizer Market will touch USD 3.6 billion by 2026

https://pharmaphorum.com/partner-content/hand-sanitizer-market-will-touch-usd-3-6-billion-by-2026/

After Celgene deal, BMS shoots up pharma market cap rankings

After Celgene deal, BMS shoots up pharma market cap rankings

Bristol-Myers Squibb $74 billion takeover of Celgene saw it shoot up the list of top 20 pharma companies

X

After Celgene deal, BMS shoots up pharma market cap rankings

https://pharmaphorum.com/news/after-celgene-deal-bms-shoots-up-pharma-market-cap-rankings/

Regeneron gets closer to ISA Pharma with new immuno-oncology alliance

Regeneron gets closer to ISA Pharma with new immuno-oncology alliance

Regeneron has doubled down in its ongoing collaboration with ISA Pharma, taking a bigger stake in the Dutch

X

Regeneron gets closer to ISA Pharma with new immuno-oncology alliance

https://pharmaphorum.com/news/regeneron-gets-closer-to-isa-pharma-with-new-immuno-oncology-alliance/

NICE rejects Sanofi’s Cablivi for rare blood disorder TTP

NICE rejects Sanofi’s Cablivi for rare blood disorder TTP

NICE has rejected Sanofi’s Cablivi (caplacizumab) for the rare blood disorder thrombotic thrombocytic purpura (TTP) in first draft guidance. The cost-effectiveness body said

X

NICE rejects Sanofi’s Cablivi for rare blood disorder TTP

https://pharmaphorum.com/news/nice-rejects-sanofis-cablivi-for-rare-blood-disorder-ttp/

1 2 3 4 5 >»

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com